Status: Recruiting
A Study of EBC-129 in Advanced Solid Tumours
This study will assess the safety and tolerability of EBC-129 as a single agent and in combination with pembrolizumab in patients with advanced solid tumours
Participants needed: 98
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: EDDC (Experimental Drug Development Centre), A*STAR Research EntitiesUpdated: Feb 5, 2026Locations: 5
Eligibility criteria
Male or female patients ≥18 years (US) or ≥21 years (Singapore) old [+5]
Unable or not willing to provide tumour tissue sample (from archival tissue or d... [+14]